Bankole Israel Adeyemi
Research Subjects
Bankole Israel Adeyemi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ikechukwu Kanu
Department of Chemistry, Ball State University, Muncie Indiana
2 shared publications - Olukunle O. Akanbi
Department of Psychology and Behavioral Sciences, National Louis University, FL, USA
2 shared publications - Abdullateef M. Busari1 shared publication
- Abdulmojeed Aishat O
Hospital Management Board Ogun State, Abeokuta, Nigeria
1 shared publication - Bostock Chinecherem Okafor
Department of Medicine and Surgery, College of Health Sciences, University of Abuja, Federal Capital Territory, Nigeria
1 shared publication Comfort Ohunene Mathew
1 shared publication
Latest Publications
- 11 January 2025
- Published by IK Press in Asian Journal of Microbiology and Biotechnology
- Vol. 10 (1) , 131-146
Progress and Prospects in HIV Vaccine Development: A Comprehensive Review
HIV/AIDS has been a disease condition affecting the entire world since its discovery in the 1980s, with over 38 million people in the globe living with the virus. Several attempts, research and funds have been channelled towards discovering a cure for HIV/AIDS yet no cure has been discovered. Considering the burden associated with the disease condition, having a vaccine to help control the spread will be a great approach in the course of achieving universal control coverage of the disease condition and an end to the disease over time. In this review we examined the progress, challenges, and future directions in HIV vaccine development and various types of vaccine candidates currently under investigation, highlighting key drug candidates that failed to provide protection against HIV such as PrEPVacc, HVTN 505, Uhambo (HVTN 702), Imbokodo (HVTN 705) and Mosaico (HVTN 706) as well as RV144 that provided 31.2% protection against HIV in a modified intent-to-treat analysis and those whose investigations are still in progress. The search for HIV Vaccine continues despite the modest success of some vaccines in clinical trials due to diversity in genetic nature of HIV, its ability to mutate rapidly, and the difficulty of eliciting a sustained immune response. Hence we also reviewed current approaches to improve on the success rate recorded by RV144.
- 11 January 2025
- Published by IK Press in Asian Journal of Microbiology and Biotechnology
- Vol. 10 (1) , 131-146
Progress and Prospects in HIV Vaccine Development: A Comprehensive Review
HIV/AIDS has been a disease condition affecting the entire world since its discovery in the 1980s, with over 38 million people in the globe living with the virus. Several attempts, research and funds have been channelled towards discovering a cure for HIV/AIDS yet no cure has been discovered. Considering the burden associated with the disease condition, having a vaccine to help control the spread will be a great approach in the course of achieving universal control coverage of the disease condition and an end to the disease over time. In this review we examined the progress, challenges, and future directions in HIV vaccine development and various types of vaccine candidates currently under investigation, highlighting key drug candidates that failed to provide protection against HIV such as PrEPVacc, HVTN 505, Uhambo (HVTN 702), Imbokodo (HVTN 705) and Mosaico (HVTN 706) as well as RV144 that provided 31.2% protection against HIV in a modified intent-to-treat analysis and those whose investigations are still in progress. The search for HIV Vaccine continues despite the modest success of some vaccines in clinical trials due to diversity in genetic nature of HIV, its ability to mutate rapidly, and the difficulty of eliciting a sustained immune response. Hence we also reviewed current approaches to improve on the success rate recorded by RV144.
- 11 January 2025
- Published by IK Press in Asian Journal of Microbiology and Biotechnology
- Vol. 10 (1) , 115-130
Biomarkers for Tuberculosis Diagnosis and Monitoring: A Review of Translational Progress
Tuberculosis (TB) still presents a major threat to public health, and accurate diagnosis of tuberculosis, monitoring TB treatment, as well as TB drug resistance are still challenging goals. Research in biomarkers—both host, pathogen pathogen-derived—has led to novel frontiers in the diagnosis and management of TB. These advancements contribute to faster diagnosis, customized treatment plans, and better monitoring of response to therapy. Direct pathogen-based markers, such as M. tuberculosis DNA, lipoarabinomannan (LAM), and mycobacterial proteins, that directly demonstrate infection, have the most potential, particularly in resource-poor settings. Cytokines such as interferon-gamma (IFN-γ) and inflammatory markers, such as C-reactive protein (CRP), are endogenous biomarkers that mirror responses of the immune system and may play a role in the management of treatment, especially in immunocompromised populations, such as patients with HIV. These progresses notwithstanding, the application of a biomarker-centered approach on a large scale remains a major obstacle, due to technical, economic, and regulatory constraints. Furthermore, various performances among the biomarkers in different populations limit clinical utility. Future studies in this area should aim to create point-of-care diagnostics, multi-biomarker panels, and to integrate the device with digital health technology platforms for real-time monitoring. These methods have the potential to substantially improve TB control, particularly in low- and middle-income countries. If current challenges can be overcome and research horizons broadened, biomarker-driven diagnosis and monitoring strategies may have key contributions in global TB control.
- 11 January 2025
- Published by IK Press in Asian Journal of Microbiology and Biotechnology
- Vol. 10 (1) , 115-130
Biomarkers for Tuberculosis Diagnosis and Monitoring: A Review of Translational Progress
Tuberculosis (TB) still presents a major threat to public health, and accurate diagnosis of tuberculosis, monitoring TB treatment, as well as TB drug resistance are still challenging goals. Research in biomarkers—both host, pathogen pathogen-derived—has led to novel frontiers in the diagnosis and management of TB. These advancements contribute to faster diagnosis, customized treatment plans, and better monitoring of response to therapy. Direct pathogen-based markers, such as M. tuberculosis DNA, lipoarabinomannan (LAM), and mycobacterial proteins, that directly demonstrate infection, have the most potential, particularly in resource-poor settings. Cytokines such as interferon-gamma (IFN-γ) and inflammatory markers, such as C-reactive protein (CRP), are endogenous biomarkers that mirror responses of the immune system and may play a role in the management of treatment, especially in immunocompromised populations, such as patients with HIV. These progresses notwithstanding, the application of a biomarker-centered approach on a large scale remains a major obstacle, due to technical, economic, and regulatory constraints. Furthermore, various performances among the biomarkers in different populations limit clinical utility. Future studies in this area should aim to create point-of-care diagnostics, multi-biomarker panels, and to integrate the device with digital health technology platforms for real-time monitoring. These methods have the potential to substantially improve TB control, particularly in low- and middle-income countries. If current challenges can be overcome and research horizons broadened, biomarker-driven diagnosis and monitoring strategies may have key contributions in global TB control.